Literature DB >> 19352463

Accomplishments in 2007 in the treatment of advanced colorectal cancer.

Richard M Goldberg1, Alfredo Carrato.   

Abstract

Overview of the Disease IncidencePrognosis Prognostic or Predictive FactorsCurrent General Therapy Standards and Regional Variations STANDARDS IN THE US AND EUROPE: Combination Therapy Plus a Biologic FOCUS and CAIRO 1: Serial Single Agents vs. Combination TherapyStop-and-Go StrategyLimited Availability of Biologics in Some RegionsAccomplishments During the Year TherapyWhat Needs To Be Done Controversies and Disagreements BOND-2 and PACCE: Chemotherapy + Bevacizumab + Cetuximab or PanitumumabSpecial Populations (Elderly and Poor Performance Status)Future Directions Comments on ResearchObstacles to Progress.

Entities:  

Year:  2008        PMID： 19352463      PMCID： PMC2664904     

Source DB:  PubMed          Journal:  Gastrointest Cancer Res        ISSN： 1934-7820


  19 in total

1.  Use of calcium and magnesium salts to reduce oxaliplatin-related neurotoxicity.

Authors:  Howard S Hochster; Axel Grothey; Barrett H Childs
Journal:  J Clin Oncol       Date:  2007-07-30       Impact factor: 44.544

2.  Nuclear factor-kB tumor expression predicts response and survival in irinotecan-refractory metastatic colorectal cancer treated with cetuximab-irinotecan therapy.

Authors:  Mario Scartozzi; Italo Bearzi; Chiara Pierantoni; Alessandra Mandolesi; Fotios Loupakis; Alberto Zaniboni; Vincenzo Catalano; Antonello Quadri; Fausto Zorzi; Rossana Berardi; Tommasina Biscotti; Roberto Labianca; Alfredo Falcone; Stefano Cascinu
Journal:  J Clin Oncol       Date:  2007-09-01       Impact factor: 44.544

3.  Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data.

Authors:  Arduino Verdecchia; Silvia Francisci; Hermann Brenner; Gemma Gatta; Andrea Micheli; Lucia Mangone; Ian Kunkler
Journal:  Lancet Oncol       Date:  2007-09       Impact factor: 41.316

4.  Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study.

Authors:  Leonard B Saltz; Heinz-Josef Lenz; Hedy L Kindler; Howard S Hochster; Scott Wadler; Paulo M Hoff; Nancy E Kemeny; Ellen M Hollywood; Mithat Gonen; Marcus Quinones; Meroe Morse; Helen X Chen
Journal:  J Clin Oncol       Date:  2007-09-17       Impact factor: 44.544

5.  Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest.

Authors:  Alfredo Falcone; Sergio Ricci; Isa Brunetti; Elisabetta Pfanner; Giacomo Allegrini; Cecilia Barbara; Lucio Crinò; Giovanni Benedetti; Walter Evangelista; Laura Fanchini; Enrico Cortesi; Vincenzo Picone; Stefano Vitello; Silvana Chiara; Cristina Granetto; Gianfranco Porcile; Luisa Fioretto; Cinzia Orlandini; Michele Andreuccetti; Gianluca Masi
Journal:  J Clin Oncol       Date:  2007-05-01       Impact factor: 44.544

6.  Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab.

Authors:  Shirin Khambata-Ford; Christopher R Garrett; Neal J Meropol; Mark Basik; Christopher T Harbison; Shujian Wu; Tai W Wong; Xin Huang; Chris H Takimoto; Andrew K Godwin; Benjamin R Tan; Smitha S Krishnamurthi; Howard A Burris; Elizabeth A Poplin; Manuel Hidalgo; Jose Baselga; Edwin A Clark; David J Mauro
Journal:  J Clin Oncol       Date:  2007-08-01       Impact factor: 44.544

7.  Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab.

Authors:  Andrea Sartore-Bianchi; Mauro Moroni; Silvio Veronese; Carlo Carnaghi; Emilio Bajetta; Gabriele Luppi; Alberto Sobrero; Carlo Barone; Stefano Cascinu; Giuseppe Colucci; Enrico Cortesi; Michele Nichelatti; Marcello Gambacorta; Salvatore Siena
Journal:  J Clin Oncol       Date:  2007-08-01       Impact factor: 44.544

8.  Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group.

Authors:  Rainer Porschen; Hendrik-Tobias Arkenau; Stephan Kubicka; Richard Greil; Thomas Seufferlein; Werner Freier; Albrecht Kretzschmar; Ullrich Graeven; Axel Grothey; Axel Hinke; Wolff Schmiegel; Hans-Joachim Schmoll
Journal:  J Clin Oncol       Date:  2007-06-04       Impact factor: 44.544

9.  Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial.

Authors:  Eduardo Díaz-Rubio; Jose Tabernero; Auxiliadora Gómez-España; Bartomeu Massutí; Javier Sastre; Manuel Chaves; Alberto Abad; Alfredo Carrato; Bernardo Queralt; Juan José Reina; Joan Maurel; Encarnación González-Flores; Jorge Aparicio; Fernando Rivera; Ferrán Losa; Enrique Aranda
Journal:  J Clin Oncol       Date:  2007-06-04       Impact factor: 44.544

10.  Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial.

Authors:  Matthew T Seymour; Timothy S Maughan; Jonathan A Ledermann; Clare Topham; Roger James; Stephen J Gwyther; David B Smith; Stephen Shepherd; Anthony Maraveyas; David R Ferry; Angela M Meade; Lindsay Thompson; Gareth O Griffiths; Mahesh Kb Parmar; Richard J Stephens
Journal:  Lancet       Date:  2007-07-14       Impact factor: 79.321
View more
  1 in total

1.  Antiangiogenesis therapy in the treatment of metastatic colorectal cancer.

Authors:  Axel Grothey; Carmen Allegra
Journal:  Ther Adv Med Oncol       Date:  2012-11       Impact factor: 8.168
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.